Triamcinolone
Aristocort, Kenacort, Kenalog, Mytrex A, Nasacort, Triamcinolone, Triderm, Triesence, Xipere, Zilretta (triamcinolone) is a small molecule pharmaceutical. Triamcinolone was first approved as Aristocort on 1982-01-01. It is used to treat adrenal insufficiency, allergic rhinitis perennial, ankylosing spondylitis, atopic dermatitis, and berylliosis amongst others in the USA. The pharmaceutical is active against glucocorticoid receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Show 7 more
Trade Name
FDA
EMA
Kenalog, Nasacort, Triamcinolone, Triderm, Triesence, Xipere, Zilretta (discontinued: Allernaze, Aristocort, Aristocort a, Aristogel, Azmacort, Flutex, Kenacort, Kenalog, Nasacort, Oralone, Triacet, Triacort, Triamcinolone, Trianex, Triatex, Trivaris, Trymex)
CombinationsNystatin triamcinolone (discontinued: Myco-triacet, Mycolog-ii, Mykacet, Mytrex a, Mytrex f, Neomycin sulfate-triamcinolone, Nystatin triamcinolone, Nystatin-triamcinolone)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Triamcinolone diacetate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ARISTOCORT | Astellas Pharma | N-011960 DISCN | 1982-01-01 | 1 products |
| KENACORT | Delcor Asset | N-012515 DISCN | 1982-01-01 | 1 products |
| ARISTOCORT | Fosun Pharmaceutical | N-011685 DISCN | 1982-01-01 | 1 products |
| ARISTOCORT | Fosun Pharmaceutical | N-012802 DISCN | 1982-01-01 | 1 products, RLD |
Hide discontinued
Triamcinolone
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ARISTOCORT | Astellas Pharma | N-011161 DISCN | 1982-01-01 | 5 products |
| KENACORT | Delcor Asset | N-011283 DISCN | 1982-01-01 | 4 products |
Hide discontinued
Triamcinolone acetonide
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| KENALOG-10 | Bristol Myers Squibb | N-012041 RX | 1982-01-01 | 1 products, RLD |
| KENALOG-40 | Bristol Myers Squibb | N-014901 RX | 1982-01-01 | 1 products, RLD, RS |
| KENALOG-80 | Bristol Myers Squibb | N-014901 RX | 2019-04-12 | 1 products, RLD, RS |
| XIPERE | Bausch Health Companies | N-211950 RX | 2021-10-22 | 1 products, RLD, RS |
| NASACORT ALLERGY 24 HOUR | Sanofi | N-020468 OTC | 2013-10-11 | 1 products, RLD, RS |
| TRIESENCE | Harrow | N-022048 RX | 2007-11-29 | 1 products, RLD, RS |
| ZILRETTA | Pacira BioSciences | N-208845 RX | 2017-10-06 | 1 products, RLD, RS |
Show 9 discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| 24 hour nasal allergy | ANDA | 2025-06-09 |
| allergy nasal | ANDA | 2024-11-22 |
| allernaze | New Drug Application | 2010-11-23 |
| basic care nasal allergy | ANDA | 2022-10-13 |
| blt-25 kit | unapproved drug other | 2024-09-11 |
| bupivilog kit | unapproved drug other | 2024-12-31 |
| bupivilog procedure kit | New Drug Application | 2014-01-30 |
| calcipotriene 0.005% / triamcinolone acetonide 0.1% | unapproved drug other | 2019-05-10 |
| careone allergy relief | ANDA | 2023-10-23 |
| cortaren corticosteroid/anti-inflammatory system | ANDA | 2022-02-24 |
Show 70 more
Indications
FDA
EMA
Show 26 more
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
TRIAMCINOLONE ACETONIDE, XIPERE, BAUSCH AND LOMB INC | |||
| 2024-10-22 | NP | ||
Patent Expiration
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Triamcinolone Acetonide, Xipere, Bausch And Lomb Inc | |||
| 9937075 | 2034-05-02 | DP | |
| 9636332 | 2033-11-08 | U-3234 | |
| 8636713 | 2027-05-02 | U-3234 | |
| Triamcinolone Acetonide, Zilretta, Pacira Pharms Inc | |||
| 8828440 | 2031-08-04 | DP | |
| 9555048 | 2031-08-04 | U-2151 | |
| Triamcinolone Acetonide, Triesence, Harrow Eye | |||
| 8128960 | 2029-12-17 | DP | |
| 8211880 | 2029-03-10 | U-1257, U-1258 | |
ATC Codes
A: Alimentary tract and metabolism drugs
— A01: Stomatological preparations
— A01A: Stomatological preparations
— A01AC: Corticosteroids for local oral treatment
— A01AC01: Triamcinolone
C: Cardiovascular system drugs
— C05: Vasoprotectives
— C05A: Agents for treatment of hemorrhoids and anal fissures for topical use
— C05AA: Corticosteroids, topical for treatment of hemorrhoids and anal fissures
— C05AA12: Triamcinolone
D: Dermatologicals
— D07: Corticosteroids, dermatological preparations
— D07A: Corticosteroid dermatological preparations, plain
— D07AB: Corticosteroids, moderately potent (group ii)
— D07AB09: Triamcinolone
— D07B: Corticosteroids, combinations with antiseptics
— D07BB: Corticosteroids, moderately potent, combinations with antiseptics
— D07BB03: Triamcinolone and antiseptics
— D07C: Corticosteroids, combinations with antibiotics
— D07CB: Corticosteroids, moderately potent, combinations with antibiotics
— D07CB01: Triamcinolone and antibiotics
— D07X: Corticosteroids, other combinations
— D07XB: Corticosteroids, moderately potent, other combinations
— D07XB02: Triamcinolone
H: Systemic hormonal preparations, excl. sex hormones and insulins
— H02: Corticosteroids for systemic use
— H02A: Corticosteroids for systemic use, plain
— H02AB: Glucocorticoids, systemic
— H02AB08: Triamcinolone
R: Respiratory system drugs
— R01: Nasal preparations
— R01A: Decongestants and other nasal preparations for topical use
— R01AD: Corticosteroid nasal preparations for topical use
— R01AD11: Triamcinolone
— R03: Drugs for obstructive airway diseases
— R03B: Other drugs for obstructive airway diseases, inhalants in atc
— R03BA: Glucocorticoid inhalants for obstructive airway disease
— R03BA06: Triamcinolone
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01B: Antiinflammatory agents, ophthalmologic
— S01BA: Corticosteroid ophthalmologic antiinflammatory agents, plain
— S01BA05: Triamcinolone
— S02: Otologicals
— S02C: Corticosteroids and antiinfectives in combination, otologic
— S02CA: Corticosteroids and antiinfectives in combination
— S02CA04: Triamcinolone and antiinfectives
HCPCS
Code | Description |
|---|---|
| J3299 | Injection, triamcinolone acetonide (xipere), 1 mg |
| J3300 | Injection, triamcinolone acetonide, preservative free, 1 mg |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
| J3302 | Injection, triamcinolone diacetate, per 5 mg |
| J3303 | Injection, triamcinolone hexacetonide, per 5 mg |
| J3304 | Injection, triamcinolone acetonide, preservative-free, extended-release, microsphere formulation, 1 mg |
| J7683 | Triamcinolone, inhalation solution, compounded product, administered through dme, concentrated form, per milligram |
| J7684 | Triamcinolone, inhalation solution, compounded product, administered through dme, unit dose form, per milligram |
Clinical
Clinical Trials
1053 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Macular edema | D008269 | — | — | 14 | 21 | 27 | 7 | 21 | 82 |
| Osteoarthritis | D010003 | EFO_0002506 | M15-M19 | 6 | 17 | 11 | 25 | 26 | 82 |
| Knee osteoarthritis | D020370 | EFO_0004616 | M17 | 6 | 17 | 13 | 24 | 20 | 73 |
| Edema | D004487 | — | R60.9 | 10 | 14 | 14 | 3 | 11 | 47 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 2 | 19 | 18 | 1 | 11 | 46 |
| Bursitis | D002062 | EFO_1000941 | M71.9 | 2 | 1 | 2 | 3 | 34 | 42 |
| Oral lichen planus | D017676 | — | — | 11 | 9 | 4 | 10 | 9 | 40 |
| Lichen planus | D008010 | — | L43 | 8 | 7 | 2 | 7 | 8 | 31 |
| Keloid | D007627 | EFO_0004212 | L91.0 | 4 | 8 | 3 | 9 | 10 | 30 |
| Syndrome | D013577 | — | — | 1 | 5 | 3 | 3 | 19 | 30 |
Show 175 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoma | D008223 | — | C85.9 | 7 | 10 | 2 | — | 3 | 18 |
| Leukemia | D007938 | — | C95 | 4 | 8 | 1 | — | — | 12 |
| Graft vs host disease | D006086 | — | D89.81 | 2 | 6 | 3 | — | 2 | 12 |
| Myelodysplastic syndromes | D009190 | — | D46 | 1 | 6 | 2 | — | — | 9 |
| Hodgkin disease | D006689 | — | C81 | 3 | 5 | 2 | — | — | 8 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 3 | 4 | 1 | — | — | 7 |
| Hepatocellular carcinoma | D006528 | — | C22.0 | 1 | 5 | 2 | — | 1 | 7 |
| Gouty arthritis | D015210 | — | — | — | 1 | 4 | — | 1 | 6 |
| Cicatrix | D002921 | — | L90.5 | 1 | 1 | 1 | — | 4 | 6 |
| Posterior uveitis | D015866 | EFO_1001119 | — | 1 | 2 | 2 | — | 2 | 6 |
Show 76 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Asthma | D001249 | EFO_0000270 | J45 | — | 2 | — | — | 4 | 6 |
| T-cell lymphoma | D016399 | — | — | 1 | 5 | — | — | — | 6 |
| T-cell lymphoma cutaneous | D016410 | — | C84.A | 1 | 2 | — | — | 1 | 4 |
| Aphthous stomatitis | D013281 | EFO_0003938 | K12.0 | — | 2 | — | — | 2 | 4 |
| Stomatitis | D013280 | EFO_1001904 | K12.1 | — | 2 | — | — | 2 | 4 |
| Therapeutics | D013812 | — | — | — | 1 | — | — | 2 | 3 |
| T-cell lymphoma peripheral | D016411 | — | — | — | 3 | — | — | — | 3 |
| Triple negative breast neoplasms | D064726 | — | — | — | 2 | — | — | 1 | 3 |
| Male breast neoplasms | D018567 | — | — | — | 1 | — | — | 2 | 3 |
| Hematologic neoplasms | D019337 | — | — | 1 | 2 | — | — | — | 3 |
Show 78 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neuralgia | D009437 | EFO_0009430 | — | 1 | — | — | — | 2 | 3 |
| Paranasal sinus diseases | D010254 | — | — | 1 | — | — | — | 1 | 2 |
| Glandular and epithelial neoplasms | D009375 | — | — | 2 | — | — | — | — | 2 |
| Myoepithelioma | D009208 | — | — | 2 | — | — | — | — | 2 |
| Burns | D002056 | — | T30.0 | 1 | — | — | — | 1 | 2 |
| Leiomyoma | D007889 | — | D25 | 1 | — | — | — | — | 1 |
| Adenomyosis | D062788 | EFO_1001757 | N80.0 | 1 | — | — | — | — | 1 |
| Squamous cell carcinoma of head and neck | D000077195 | — | — | 1 | — | — | — | — | 1 |
| Vasoconstriction | D014661 | — | — | 1 | — | — | — | — | 1 |
| Papilledema | D010211 | EFO_1001074 | H35.81 | 1 | — | — | — | — | 1 |
Show 11 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Membranous glomerulonephritis | D015433 | EFO_0004254 | N03.2 | — | — | — | — | 5 | 5 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | — | — | — | 4 | 4 |
| Mastitis | D008413 | EFO_1001034 | N61 | — | — | — | — | 4 | 4 |
| Retinal perforations | D012167 | EFO_1001028 | — | — | — | — | — | 4 | 4 |
| Granulomatous mastitis | D058890 | — | N61.2 | — | — | — | — | 3 | 3 |
| Physical therapy modalities | D026741 | — | — | — | — | — | — | 3 | 3 |
| Rehabilitation | D012046 | — | — | — | — | — | — | 3 | 3 |
| Peripheral nervous system diseases | D010523 | — | G64 | — | — | — | — | 3 | 3 |
| Acne vulgaris | D000152 | EFO_0003894 | L70 | — | — | — | — | 3 | 3 |
| Oral ulcer | D019226 | — | — | — | — | — | — | 3 | 3 |
Show 137 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Triamcinolone |
| INN | triamcinolone |
| Description | Triamcinolone is a C21-steroid hormone that is 1,4-pregnadiene-3,20-dione carrying four hydroxy substituents at positions 11beta, 16alpha, 17alpha and 21 as well as a fluoro substituent at position 9. Used in the form of its 16,17-acetonide to treat various skin infections. It has a role as an anti-allergic agent and an anti-inflammatory drug. It is a fluorinated steroid, an 11beta-hydroxy steroid, a 20-oxo steroid, a 21-hydroxy steroid, a 3-oxo-Delta(4) steroid, a glucocorticoid, a 17alpha-hydroxy steroid, a 16alpha-hydroxy steroid, a C21-steroid hormone, a primary alpha-hydroxy ketone and a tertiary alpha-hydroxy ketone. It derives from a hydride of a pregnane. |
| Classification | Small molecule |
| Drug class | steroids (not prednisolone derivatives) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C[C@]12C[C@H](O)[C@@]3(F)[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1C[C@@H](O)[C@]2(O)C(=O)CO |
Identifiers
| PDB | — |
| CAS-ID | 124-94-7 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1451 |
| ChEBI ID | 9667 |
| PubChem CID | 31307 |
| DrugBank | DB00620 |
| UNII ID | 1ZK20VI6TY (ChemIDplus, GSRS) |
Target
Agency Approved
NR3C1
NR3C1
Organism
Homo sapiens
Gene name
NR3C1
Gene synonyms
GRL
NCBI Gene ID
Protein name
glucocorticoid receptor
Protein synonyms
Nuclear receptor subfamily 3 group C member 1, nuclear receptor subfamily 3 group C member 1 variant hGR-B(54), nuclear receptor subfamily 3 group C member 1 variant hGR-B(77), nuclear receptor subfamily 3 group C member 1 variant hGR-B(93), nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor)
Uniprot ID
Mouse ortholog
Nr3c1 (14815)
glucocorticoid receptor (Q61629)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Zilretta – Pacira BioSciences
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Zilretta – Flexion Therapeutics
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Triamcinolone
+
Nystatin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Triamcinolone
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 25,719 documents
View more details
Safety
Black-box Warning
Black-box warning for: Blt-25 kit, Bupivilog kit, Mlk f1 kit, Mlk f3 kit, Mlk f4 kit, Mlk kit f2
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
27,289 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use